Mechanism of Action of Antibiotics: 5 Types and Classification

A patient with a serious Pseudomonas infection is started on two antibiotics at once. A colleague asks why the ward almost never gives vancomycin for a gram-negative bloodstream infection, no matter how sick the patient is. And a first-year student cannot see why penicillin, which is deadly to bacteria, is almost harmless to the person swallowing it.

Every one of these everyday questions has the same answer: it depends on where the antibiotic attacks the bacterial cell, and whether the human host has that same target. Understand the mechanism of action, and the spectrum, the toxicity, and the resistance patterns stop being lists to memorize and start being things you can reason out.

How antibiotics work

An antibiotic works by binding to a structure or a pathway that a bacterium needs to survive or multiply, and jamming it. The trick that makes an antibiotic safe to give to a person is selective toxicity: the target is something the bacterial cell has but the human cell does not, such as the peptidoglycan cell wall, or something the bacterium builds differently from us, such as its 70S ribosome or its own folate supply.

There are five main targets, and almost every antibiotic you will meet acts on one of them.

The 5 mechanisms of action of antibiotics

That table is the whole article in miniature. The rest of this article explains each row, shows you how to remember them, and points you to a dedicated article for each drug class.

Why the mechanism is the thing worth learning

Learning drugs one brand name at a time does not scale, and it is not how clinical decisions are actually made. The mechanism is the organizing idea that everything else hangs on:

• It predicts the spectrum. A drug that attacks peptidoglycan cross-linking will fail against an organism that has no meaningful cell wall, such as Mycoplasma, and against gram-negatives whose outer membrane keeps the drug out.
• It predicts toxicity. Drugs that hit a target humans share, such as the cell membrane, tend to be toxic and are used sparingly. Drugs that hit a bacteria-only target, such as the cell wall, are among the safest we have.
• It predicts resistance. Every mechanism of action has a matching mechanism of resistance. If a drug binds a penicillin-binding protein, expect resistance that alters that protein (this is exactly how MRSA defeats beta-lactams) or that destroys the drug first (beta-lactamases).
  
  Mechanism of action and mechanism of resistance are two sides of one coin, which is why this article pairs with Antibiotic Resistance: Origin, Causes, Mechanism.
• It predicts sensible combinations. Knowing that a cell-wall agent needs actively growing bacteria, and that some protein-synthesis inhibitors stop that growth, is the starting point for understanding why certain pairings help and others work against each other.

Classification of antibiotics

Antibiotics are grouped in more than one way, and exam questions lean on all of them. The four that matter most:

1. By mechanism of action (the five targets above). This is the most useful clinical grouping and the backbone of this article.

2. By chemical structure (the drug class). Drugs of the same structure tend to share effectiveness, spectrum, and toxicity. The standard structural classes are beta-lactams, glycopeptides, aminoglycosides, tetracyclines, macrolides, fluoroquinolones, sulfonamides, and oxazolidinones.

3. By whether they kill or merely stop bacteria. A bactericidal drug kills the bacterium. A bacteriostatic drug halts its growth and reproduction and leaves the final killing to the host immune system. This distinction matters most when the immune system is weak, as in the classic teaching example of bacterial meningitis or in a neutropenic patient, where a killing drug is preferred.

4. By killing kinetics (how the dose should be timed). Some drugs kill harder the higher the peak concentration goes; others kill based on how long the drug stays above the threshold. This is why aminoglycosides are given as one big daily dose while penicillins are given more frequently or as an extended infusion. See more about aminoglycosides: mechanism of action and resistance.

For a policy-level grouping used in stewardship (Access, Watch, Reserve), see WHO AWaRe Classification of Antibiotics.

The five mechanisms in detail

This is article each drug class gets the essential idea and a link to its own dedicated article.

1. Inhibition of cell wall synthesis

The bacterial cell wall is a mesh of peptidoglycan: chains of two sugars, N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG), cross-linked through short peptide side chains. The final cross-link, between the D-alanyl-D-alanine ends of neighboring peptides, is stapled together by enzymes called penicillin-binding proteins (PBPs). A wall that cannot be cross-linked cannot hold pressure, and the cell bursts.

• Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams): the beta-lactam ring mimics D-alanyl-D-alanine, so the PBP grabs the drug instead of its real substrate and is taken out of action. See Beta-Lactam antibiotics: mechanism of action and resistance.
• Glycopeptides (vancomycin, teicoplanin): bind the D-alanyl-D-alanine terminus itself, physically blocking the PBP from reaching it. Too large to cross the gram-negative outer membrane, which is why they are gram-positive drugs. See Glycopeptides.
• Bacitracin: blocks recycling of the lipid carrier that ferries peptidoglycan precursors across the membrane.

2. Inhibition of protein synthesis

Bacteria build proteins on a 70S ribosome made of a 30S and a 50S subunit. Human cells use an 80S ribosome, so the difference is the basis for selective toxicity. Antibiotics jam one subunit or the other.

• Acting on the 30S subunit: aminoglycosides (gentamicin, neomycin, streptomycin, amikacin) cause misreading of the genetic code and are bactericidal; tetracyclines block the incoming aminoacyl-tRNA and are bacteriostatic. See Tetracyclines: Mode of Action and Mechanism of Resistance.
• Acting on the 50S subunit: macrolides (erythromycin, azithromycin), chloramphenicol, clindamycin, and linezolid (an oxazolidinone) each block a step of peptide bond formation or elongation. See Macrolides: Mode of Action, Mechanism of Resistance.

3. Inhibition of nucleic acid synthesis

Bacteria must copy DNA and transcribe it to RNA, using enzymes different enough from ours to be drug targets.

• Fluoroquinolones (ciprofloxacin, levofloxacin) and the older quinolones (nalidixic acid) inhibit DNA gyrase and topoisomerase IV, the enzymes that manage DNA supercoiling during replication. See more: Fluoroquinolones: Mode of Actions and Mechanism of Resistance.
• Rifamycins (rifampicin) bind the DNA-dependent RNA polymerase and block the start of transcription.

4. Inhibition of folate synthesis

Folate is needed to build the bases of DNA and RNA. Humans get folate from food; bacteria must make their own, so the pathway is a bacteria-only target.

• Sulfonamides mimic PABA and block dihydropteroate synthase (the first step).
• Trimethoprim blocks dihydrofolate reductase (a later step).
• Given together as co-trimoxazole, they block two sequential steps, act synergistically, and lower the mutation rate for resistance.

5. Disruption of the cell membrane

The cytoplasmic membrane holds the cell's contents in and runs its transport. A drug that punches holes in it causes leakage and rapid death, but because human cells also have membranes, these drugs are relatively toxic and are used when little else works.

• Polymyxins (polymyxin B, colistin) act like detergents on the gram-negative outer and inner membranes.
• Daptomycin inserts into the gram-positive membrane and collapses its charge gradient.
• Gram-positive bacteria are intrinsically resistant to polymyxins, and gram-negatives to vancomycin, for opposite structural reasons. Worked examples like these live in Bacteria Associated with Intrinsic Antibiotic Resistance.

How to remember all of this

The factory analogy for the five targets. Picture the bacterium as a walled factory. The cell wall is the perimeter wall, the ribosome is the assembly line making the products, the DNA and RNA are the blueprints in the office, folate is the paper the blueprints are printed on, and the membrane is the fence around the perimeter. An antibiotic sabotages exactly one of these five: breach the wall, jam the assembly line, shred the blueprints, cut off the paper supply, or tear down the fence.

30S versus 50S: "buy AT 30, CCELL at 50." The 30S inhibitors are Aminoglycosides and Tetracyclines. The 50S inhibitors are Chloramphenicol, Clindamycin, Erythromycin (macrolides), Linezolid, and Lincosamides/streptogramins.

Bactericidal versus bacteriostatic. Most protein-synthesis and folate drugs are static; most cell-wall, DNA, and RNA drugs are cidal. A handy static list is "ECSTaTiC": Erythromycin, Clindamycin, Sulfonamides, Trimethoprim, Tetracyclines, Chloramphenicol. Aminoglycosides are the famous exception: they inhibit protein synthesis yet kill.

Where students actually get confused

Bacteriostatic does not mean weak. A static drug can cure a healthy patient perfectly well because their immune system finishes the job. The distinction becomes important mainly when host defenses are compromised.

Why aminoglycosides are cidal when other protein-synthesis inhibitors are static. Most 30S and 50S drugs simply pause protein production, which is reversible. Aminoglycosides cause the ribosome to build faulty proteins that damage the membrane, and their binding is effectively irreversible, so the cell dies.

30S versus 50S mix-ups. Only two common classes hit the 30S (aminoglycosides and tetracyclines); everything else in the protein-synthesis group is a 50S drug. Learn the short 30S list and the rest fall into place.

Why folate drugs spare human cells. We eat folate, so blocking its synthesis does nothing to us. Bacteria must synthesize it, so the block is lethal to them. This is selective toxicity in its purest form.

Cell-wall agents need growing bacteria. Beta-lactams and vancomycin only work on cells that are actively building wall. A dormant, non-dividing bacterium is much harder for them to kill, which is part of why deep-seated or biofilm infections are stubborn.

"Resistant" is not the same as "the drug never worked here." A gram-negative that vancomycin cannot reach is intrinsically resistant by its anatomy, which is different from an acquired resistance a strain picks up. The two are separated cleanly in Antibiotic Resistance: Origin, Causes, Mechanism.

Key exam facts

References

1. Kapoor G, Saigal S, Elongavan A (2017). Action and resistance mechanisms of antibiotics: A guide for clinicians. Journal of Anaesthesiology Clinical Pharmacology, 33(3): 300-305. DOI: 10.4103/joacp.JOACP_349_15
2. Etebu E, Arikekpar I (2016). Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. International Journal of Applied Microbiology and Biotechnology Research, 4: 90-101.
3. Reygaert WC (2018). An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiology, 4(3): 482-501. DOI: 10.3934/microbiol.2018.3.482
4. Kirmusaoglu S, Gareayaghi N, Kocazeybek BS (2019). Introductory Chapter: The Action Mechanisms of Antibiotics and Antibiotic Resistance. In Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods. IntechOpen. DOI: 10.5772/intechopen.85211
5. Katzung BG (ed.) (2021). Basic and Clinical Pharmacology, 15th edition. McGraw Hill. Chapters on cell wall, protein synthesis, and nucleic acid synthesis inhibitors.
6. Antimicrobial Drugs and Selective Toxicity. Biology LibreTexts, Microbiology (Boundless), section 13.1.